Aurobindo Pharma gets USFDA EIR for Hyderabad facility
New Delhi: Aurobindo Pharma has recently announced that the company has received an Establishment Inspection Report (EIR) from the USFDA with Voluntary Action Initiated (VAI) status at the conclusion of the inspection of the company's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad.
Voluntary Action Indicated (VAI) means objectionable conditions or practices were found but the agency is not prepared to take or recommend any administrative or regulatory action.
"The Company's Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, received an Establishment Inspection Report (EIR) mentioning the inspection a Voluntary Action Initiated (VAl) from the USFDA and with this inspection is concluded," the company stated in BSE filing.
Medical Dialogues Team had earlier reported that the USFDA had concluded an inspection with six observations at its Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.